Kenvue

Waardering

K/W (TTM)

20,65

K/W (verwacht)

14,03

Winst per aandeel

US$ 0,84

Koers/boekwaarde

3,14

Bèta

0,52

Kerncijfers

Omzet (TTM)

US$ 15,29 mld

EBITDA

US$ 3,47 mld

Winstmarge

10,61%

Rendement eigen verm. (ROE)

15,70%

Omzetgroei

4,50%

Uitstaande aandelen

1.920.008.668

Dividend

Dividendrendement

4,78%

Dividend p/a

US$ 0,83

Uitkeringsratio

98,51%

Over Kenvue

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.